Physician profile
Rolvix Patterson
NPI 1073507687
$8,280.13
in general payments reported to CMS, 2019-2025
29 companies · $1,493 in 2025
The $1,493 reported for 2025 was more than what 93% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $52.30 · 2021: $5,619 · 2022: $256 · 2023: $238 · 2024: $297 · 2025: $1,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,366 · Food and Beverage: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,366.12 |
| Food and Beverage | $661.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,619.42 | 2021 | |
| Medtronic, INC. | $1,405.26 | 2022-2025 | Truclear |
| Organon LLC | $137.13 | 2022-2025 | Nexplanon |
| Pfizer INC. | $108.13 | 2019-2024 | |
| Novo Nordisk INC | $93.02 | 2019-2024 | Wegovy, Saxenda |
| Sumitomo Pharma America, INC. | $89.89 | 2023-2024 | Myfembree, Gemtesa |
| Abbvie INC. | $79.81 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.31 | 2019-2023 | |
| Daiichi Sankyo INC. | $71.71 | 2019-2024 | Injectafer |
| Meditrina | $70.24 | 2022 | |
| Lsi Solutions INC | $59.27 | 2023 | Fornisee |
| Biogen, INC. | $57.07 | 2024-2025 | Zurzuvae |
| Amgen INC. | $52.64 | 2019 | |
| Amag Pharmaceuticals, INC. | $45.54 | 2019 | |
| Merck Sharp & Dohme LLC | $37.65 | 2019-2023 | Gardasil 9 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $29.30 | 2019 | |
| Davol INC. | $25.23 | 2022 | |
| Mayne Pharma Commercial LLC | $24.89 | 2025 | |
| Therapeuticsmd, INC. | $23.92 | 2019-2020 | |
| Roche Diagnostics Corporation | $23.89 | 2020 | |
| Myovant Sciences INC. | $23.62 | 2022 | |
| Hologic Sales and Service, LLC | $21.26 | 2025 | Thinprep 2000 Processor, Aptima |
| Sanofi Pasteur INC. | $17.46 | 2025 | |
| Exeltis, USA INC. | $17.22 | 2024 | Slynd |
| Lilly USA, LLC | $17.05 | 2024 | Zepbound, Jardiance |
| Duchesnay USA Incorporated | $16.24 | 2019 | |
| Boston Scientific Corporation | $15.28 | 2024 | Advantage System |
| Avion Pharmaceuticals | $12.07 | 2019 | |
| Allergan, INC. | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rolvix Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.